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intestinal Autophagy and its 
Pharmacological Control in 
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Ping Ke†, Bo-Zong Shao†, Zhe-Qi Xu, Xiong-Wen Chen* and Chong Liu*
Department of Pharmacology, Second Military Medical University, Shanghai, China
Intestinal mucosal barrier, mainly composed of the intestinal mucus layer and the epi-
thelium, plays a critical role in nutrient absorption as well as protection from pathogenic 
microorganisms. It is widely acknowledged that the damage of intestinal mucosal barrier 
or the disturbance of microorganism balance in the intestinal tract contributes greatly to 
the pathogenesis and progression of inflammatory bowel disease (IBD), which mainly 
includes Crohn’s disease and ulcerative colitis. Autophagy is an evolutionarily conserved 
catabolic process that involves degradation of protein aggregates and damaged 
organelles for recycling. The roles of autophagy in the pathogenesis and progression 
of IBD have been increasingly studied. This present review mainly describes the roles 
of autophagy of Paneth cells, macrophages, and goblet cells in IBD, and finally, several 
potential therapeutic strategies for IBD taking advantage of autophagy.
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iNTRODUCTiON
The intestinal tract mainly functions as the most important organ digesting and absorbing food 
and nutrients taken orally. Besides those obvious functions, the gut is also regarded as one of the 
largest immune organs in an organism since the gut lumen always harbors a great number of 
microorganisms. As a result, the host has to maintain the peaceful coexistence with this diverse 
microbial community and trigger the inflammatory and immune reaction for the detection and 
elimination of the pathogenic microorganisms (1, 2). During this process, an efficient intestinal 
mucosal barrier is critical for the maintenance of microbial homeostasis and fighting against patho-
genic microorganisms, providing the first line of defense. In general, the intestinal mucosal barrier 
is composed of two layers, including the intestinal mucus layer and the epithelium, in combination 
with the equipment of diverse specific and unspecific protective mechanisms which collectively build 
up an effective intestinal mucosal barrier (3). However, the disturbance of microbial homeostasis 
and damage of intestinal mucosal barrier largely trigger the inflammatory responses, immune 
reaction, accumulation of reactive oxygen species (ROS), and mitochondrial dysfunction in the 
intestinal wall, finally leading to the pathogenesis and progression of inflammatory bowel disease 
(IBD). As a result, inhibiting the over-activation of those self-defensive processes may serve as a 
potential and effective strategy for the treatment of IBD. Autophagy is a popular self-protective 
mechanism, the function of which mainly relies on lysosome. There is much evidence to suggest that 
autophagy could effectively attenuate the over-triggering of several self-defensive pathways such as 
inflammatory reaction and immune responses (4–6). Based on the statement, autophagy has been 
increasingly studied by researchers for the development of novel and effective therapeutic strategies 
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against inflammation- or immune-related disorders, including 
IBD. Here, in this review, we discuss the mechanisms underlying 
the pathogenesis of IBD, the signaling pathways of autophagy, as 
well as the roles of autophagy in three important cells, namely, 
Paneth cells, macrophages, and goblet cells, in IBD, and, last but 
not least, several pharmacological interventions of autophagy in 
the treatment of IBD.
PATHOGeNeSiS OF iBD
We have mentioned above that the inflammatory and immune 
responses are triggered for the defense in the intestine. However, 
the over-triggered self-protective inflammatory and immune 
responses can lead to the damage of intestine itself as well as the 
intestinal mucosal barrier, contributing to the pathogenesis and 
progression of chronic inflammatory disorders, such as IBD.
Although the exact mechanisms underlying IBD have not 
yet been clarified, evidence has shown that the environment, 
genetics, and interactions between host defense and commensal 
microbiota are the main causes leading to the development of 
IBD (7). Smoking is an important environmental risk factor 
related to Crohn’s disease (CD) (8). Patients suffering from CD 
are responding badly to treatments and present more severe 
symptoms (9, 10). Another environmental factor attributing to 
IBD is air pollution (11). The particulate matter, ozone, or nitrous 
oxides in the air intrude into intestinal tract through food and 
water, which may cause an increased intestinal epithelial perme-
ability, or induce pro-inflammatory response, thus leading to 
the occurrence of IBD (12, 13). In addition, it was noticed that 
antibiotics use was a potential factor of IBD onset as antibiot-
ics could alter the amount and composition of the intestinal 
microflora, which ended up triggering abnormal inflammatory 
responses (14). The genetics of IBD were recognized by genome-
wide association studies (GWAS) showing that people harboring 
variants in innate and adaptive immunity-related genes were 
more susceptible to both ulcerative colitis (UC) and CD, such as 
nucleotide-binding oligomerization domain-containing protein 
2 (Nod2), immunity-related GTPase family protein M (IRGM), 
autophagy-related protein 16 like protein 1 (Atg16l1), interleukin 
12B (IL-12B), Drosophila mothers against decapentaplegic pro-
tein 3 (SMAD3), and others (15–17). These susceptibility genes 
lead to dysregulation of the intestinal mucosal inflammatory and 
immune system that result in excessive immunologic responses 
to normal flora or impaired ability to clearance invasive bacteria 
(18, 19). Evidence has shown that virus-plus-susceptibility gene 
interactions induced colitis similar to CD (19). The interactions 
between the host and its diverse microbial community are com-
plex and crucial in maintaining intestinal homeostasis. The intes-
tinal defense system consists of the mucus layer, epithelium, and 
cells related to the innate immune system. In normal conditions, 
the mucus layer which contains large numbers of antimicrobial 
substance and mucins works together with the epithelium to 
separate microbes from the host, and if any pathogen intrudes 
through the epithelium, the dentritic cells and macrophages of 
the immune system in intestine will recognize it and generate 
an appropriate inflammatory or immune response by producing 
cytokines and antimicrobial agents (20). However, defects in 
mucin secretion (21) or epithelial integrity (22) and malfunction 
of the immune response to restrict pathogenic microbes alone 
or together contribute to the pathogenesis of IBD. The last factor 
for the pathogenesis and progression of IBD that deserves to be 
mentioned here is the adaptive immune response. It is gener-
ally acknowledged that increased pro-inflammatory cytokines 
produced by the T-helper cells or decreased anti-inflammatory 
cytokines induced by ineffective regulatory T-cells contribute to 
the pathogenesis of IBD (23, 24). Nevertheless, since the patho-
genesis of IBD is complex and the exact underlying mechanisms 
still remain unclear, no effective therapeutic strategies have been 
developed for the treatment of IBD.
AUTOPHAGY AND iTS FUNCTiONS
Autophagy is an evolutionarily conserved catabolic process that 
involves degradation of protein aggregates and damaged orga-
nelles for recycling (25). Its function of degrading and recycling 
mainly relies on lysosome. In general, autophagy is defined into 
three types: macroautophagy, microautophagy, and chaperone-
mediated autophagy (26, 27). Microautophagy belongs to a 
non-selective degradative mechanism through invagination of 
the lysosomal/vacuolar membranes for the engulfment of cyto-
plasmic components (28). Chaperone-mediated autophagy is the 
only autophagy style that allows the degradation of organelles and 
proteins relying on the presentation of chaperones. It has been 
reported previously that chaperone-mediated autophagy largely 
demands the presence of a targeting motifin which is the sub-
strate protein, a set of cytosolic and lysosomal chaperones, and a 
receptor protein at the lysosomal membrane for the transporta-
tion into lysosome assisted by chaperone located in the lysosomal 
lumen (29). Macroautophagy is a catabolic process, during which 
intracellular components or invasive bacteria are surrounded by 
double-membrane-bound structures, widely acknowledged as 
autophagosome. After the confusion of autophagosome and lyso-
some, the degradative autolysosome with single-layer membrane 
is formed for the digestion of ingredients by lysozymes (30, 31). 
Since macroautophagy is, so far, the best-studied autophagy 
process, this review will mainly discuss the functions and roles 
of macroautophagy in IBD (hereafter referred to as “autophagy”).
In general, the induction of autophagy process is mainly 
involved in two steps. In the first step, the cup-shaped double-layer 
phagophores form in the cytoplasm, followed by the subsequent 
formation of spherical double-membraned autophagosomes 
that enclose misfolded proteins or damaged organelles for 
degradation. Autophagosomes are regarded to be shaped from 
the nucleation and membrane expansion of phagophores. In the 
second step, autophagosomes dispose of “coat proteins” named 
autophagy-related light chain 3 (LC3) on their surface followed 
by the integration with lysosomes for the formation of the single 
lipid layer membrane-surrounded autolysosomes, which are the 
functional units for degradation and digestion (32). The whole 
process is participated by more than 30 kinds of autophagy-
related genes (Atgs) and autophagy-related proteins (32, 33).
So far, several signaling pathways have been uncovered for 
the involvement of autophagy process. As recently reviewed by 
us (32), there are two major signaling pathways participating 
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in the induction and regulation of autophagy process, includ-
ing the inhibitory Class I PI3K–mTOR signaling pathway and 
the inductive Class III PI3K–Beclin-1 signaling pathway. The 
inhibitory pathway is often activated by nutrient sufficiency or 
several growth factors stimulation. In this pathway, the Class I 
PI3K–mTOR signaling is largely activated by the phosphoryla-
tion of Akt pathway and formation of mTOR complex 1, a major 
anti-autophagy complex, which in turn induces the inhibition of 
Atg1 (ULK1) to prevent the initiation of autophagosome forma-
tion. The inductive signaling pathway often occurs in the opposite 
situations like nutrient insufficiency or stimulation of the inflam-
matory or ROS stress. In this process, the Class III PI3K–Beclin-1 
complex is initially formed, which in turn promotes the assembly 
of the Atg12–Atg5–Atg16L complex and the Atg8/LC3. The trig-
gering of this signaling pathway largely induces the formation of 
autophagosomes and autophagy process.
In the fundamental studies on autophagy, the application 
of autophagy inhibitors is commonly conducted as an effective 
strategy in the exploration of autophagy mechanisms and discus-
sion on roles of autophagy in diseases. Traditionally, chemical 
inhibitors of autophagy were most widely used. According to 
the latest guidelines for the use and interpretation of assays for 
monitoring autophagy published in 2016, the chemical inhibitors 
of autophagy can be mainly divided into two categories based on 
the stages of autophagy blockade (34). The first one, including 
3-methyladenine (3-MA), LY294002, and wortmannin, belongs 
to sequestration inhibitors, relying on the inhibition of PI3Ks 
as well as class III PtdIns3Ks, thus leading to the blocking of 
the formation of autophagosomes. The second one, including 
vinblastine, leupeptin, and bafilomycin A1, is post-sequestration 
inhibitors, which leads to the accumulation of sequestered materi-
als in either autophagosomes or autolysosomes or both. However, 
researchers are increasingly aware that most chemical inhibitors 
are not entirely specific and show the dose- and time-dependent 
effects. For example, it was reported that in a certain condition for 
the application of 3-MA, autophagy might be promoted because 
of the inhibition of the class I enzyme (35). Recently, the specific 
loss-of-function Atg mutants are considered as the more effective 
approach for the blockade of autophagy process, but they may 
lead to the autophagy-independent effects and also be dispensable 
of autophagy (34). Consequently, more efforts must be made in 
order to seek the more effective and specific autophagy inhibitors.
So far, autophagy has been reported to be closely related with 
apoptosis, inflammatory response, immune reaction, ROS stress, 
and mitochondrial dysfunction, functioning as effective regula-
tor of the occurrence and extent of those processes (31, 36–38). 
As a result, it is certain that autophagy is a vital factor in the 
pathogenesis and regulation of various kinds of inflammation- 
and immune-related diseases, serving as a potential and effective 
target for the intervention of those diseases.
THe ROLeS OF AUTOPHAGY iN iBD
The roles of autophagy in the pathogenesis and progression of 
IBD has been increasingly studied by researchers recently. For 
example, GWAS have reported several Atgs like Atg16l1 and 
IRGM contributes to the susceptibility of IBD, suggesting that 
autophagy possibly mediated the pathophysiology of IBD (17, 39, 
40). In fact, autophagy affects the pathogenesis of IBD in various 
pathways, one of which is to regulate the clearance of invading 
pathogens. When the host cells were infected by bacteria, cyto-
plasmic vesicles engulfed these pathogens to form autophago-
some, thus confining them obtaining nutrients and promoting 
acidification of surroundings. The enhancement of autophagy 
promotes the integration of autophagosome and lysosome, 
leading to the degradation of pathogenic organisms (41–43). In 
addition, autophagy protects cells against the damage of bacte-
rial toxins, thus promoting cell survival such as macrophages, 
neutrophils, and intestinal epithelial cells (44). It has also been 
reported that autophagy augments adaptive immune response. 
After degraded by autolysosome, antigens are presented to the 
major histocompatibility complex class II molecules (MHC II), 
and then recognized by T cells to prime the adaptive immune 
response. This process can be promoted by autophagy (45–47). 
Evidence has shown that impaired autophagy disturbs the func-
tion of intestinal epithelial cells and influences the innate and 
adaptive immune responses, ROS production, and endoplasmic 
reticulum (ER) stress, leading to abnormal inflammatory reac-
tion, and ultimately promoting the occurrence and development 
of IBD (7, 48–50).
Moreover, it should be mentioned there exists the crosstalk 
between autophagy and the damage-associated molecular pattern 
molecules (DAMPs) release and degradation in IBD. DAMPs 
are defined as several kinds of endogenous molecules including 
the S100A calgranulins, chromatin-associated high-mobility 
group box 1 (HMGB1), heat shock proteins, interleukin (IL)-1 
family members, histones, and adenosine triphosphate (ATP), 
DNA, RNA, uric acid, hyaluronan, and heparin sulfate which are 
released by dead, dying, injured, or stressed cells (51). Previous 
studies reported that high levels of DAMPs were detected in 
serum, fecal or mucosa of IBD patients as well as mice models 
(52–55). In addition, it was demonstrated that the regulation 
of IBD progression by DAMPs was majorly through several 
approaches: (1) affecting epithelial barrier function; (2) binding 
with pattern-recognition receptors (PRRs) to exert directly pro-
inflammatory effect; and (3) assisting in antigen-presenting cells 
to regulate T cells function (56). Since DAMPs are highly relevant 
to IBD, it is extremely essential to monitor the release pattern 
of these molecules. It has been demonstrated that the levels of 
DAMPs can be decreased by autophagy through the promotion 
of DAMPs degradation (57–59). However, it was also noted that 
under certain conditions, such as starvation or the stimulation 
of cytotoxic drugs, the induced autophagy could substantially 
lead to the release of DAMPs, including HMGB1, ATP, and 
IL1B (60–62). Consequently, to ultimately take advantage of the 
inhibitory roles of autophagy on DAMPs, effective methods are 
demanded to get rid of the promoting effect of autophagy on the 
release of DAMPs.
The following parts of this paper will mainly focus on the 
influence of autophagy in three important kinds of cells, which 
are highly related to intestinal self-defense and inflammatory and 
immune reaction, namely Paneth cells, macrophages, and goblet 
cells, on IBD, and finally, several potential therapeutic strategies 
for the treatment of IBD taking advantage of autophagy.
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Paneth Cell, iBD, and Autophagy
Paneth Cell and IBD
As mentioned above, the epithelium together with mucus layer 
forms a physical barrier against the invading pathogens, includ-
ing bacteria, fungi, virus, and harmful antigens in food, while 
tolerating beneficial microbes, thus maintaining the intestinal 
homeostasis. Specifically speaking, intestinal mucus layer, a 
layer of sticky gel covering the surface of mucosa, is composed 
of proteins, lipids, and carbohydrates as well as the large amount 
of water (63, 64). In the colon or large intestine, the mucus layer 
is divided into two distinct sectors, including the inner and 
outer layers. The inner layer is densely and firmly attached to the 
epithelium, while the outer layer is relatively more removable (3, 
65). Among all of the components of mucus layer, various kinds 
of antimicrobial peptides (AMPs) are the most important func-
tional peptides, with the defensins and the cathelicidins as the two 
best featuring families of AMPs, protecting the intestinal against 
microorganisms (66). The epithelium is majorly composed of 
several kinds of intestinal epithelial cells, including absorptive 
enterocytes, goblet cells, enteroendocrine cells, and Paneth cells 
(67). The absorptive enterocytes are the most abundant cell type 
in the epithelium, since they are rich in intestinal villi (68). Goblet 
cells and enteroendocrine cells mainly functions in secretion and 
restoration of the intestinal tissue (2, 68). Paneth cells, named 
after the Austrian physiologist Joseph Paneth, are the target 
cells in this paper for discussion, since they contains various 
kinds of secretary granules with antimicrobial active substances 
like lysozyme and α-definsins, highly involved in the defensive 
inflammatory and immune response in the intestine as well as 
the pathogenesis and progression of chronic intestinal diseases 
(3, 69). A recent study demonstrated that Paneth cells were a site 
of origin for intestinal inflammation, which are situated in the 
base of crypts of Lieberkühn, harboring a large number of ER and 
Golgi apparatus. Studies conducted on them revealed their vital 
role in directing the balance between homeostasis and inflamma-
tion through releasing AMPs and peptides including lysozyme, 
lipopolysaccharide (LPS)-binding protein, matrix metallopro-
teinase-7, phospholipase A2, phospholipase B, and IgA, as well 
as inflammatory cytokines like transforming growth factor β1 
(TGF-β1), tumor necrosis factor α (TNF-α), and prostaglandin 
E2 (70–72). These AMPs could regulate the composition and 
quantity of microbes that colonize in the intestinal lumen and 
clear the intracellular pathogens.
The Roles of Paneth Cell Autophagy in IBD
In recent years, researchers discovered that autophagy and the 
autophagy gene had a specific role in the biology and function 
of Paneth cells. Cadwell et al. revealed that Atg16l1-, Atg5-, and 
Atg7-deficient Paneth cells exhibited few granules and decreased 
amounts of antimicrobial proteins and peptides inside. These 
cells also defected in granule exocytosis pathway through which 
cytoplasmic granules containing AMPs and other proteins are 
secreted to the intestinal lumen. In addition, Atg16l1-deficient 
Paneth cells presented increased expression of lipoprotein lipase, 
apolipoprotein A-IV, adiponectin, leptin, adiponectin, resistin-
like α, complement factor D (adipsin), and haptoglobin. Many 
of these genes were directly implicated in inflammation, and two 
of these transcripts, namely leptin and adiponectin, increased 
in CD patients. Likewise, CD patients who carried Atg16l1 risk 
allele showed morphology and granule abnormalities of Paneth 
cells similar to those observed in autophagy-gene-deficient mice 
and expressed increased levels of leptin protein (73–75). Different 
from decreased amounts of granules in Atg7-deficient Paneth 
cells reported by Cadwell et  al., Wittkopf et  al. found out that 
Atg7 deficiency induced increased number and smaller size of 
granules in Paneth cells. Despite the lack of Paneth cell biology, 
Atg7 deficiency did not lead to altered response toward dextran 
sodium sulfate (DSS)-induced colitis, suggesting that autophagy 
defects in intestinal epithelial cells alone was not potent enough 
to increase susceptibility to enteritis (76). This conclusion was 
further supported by Cadwell et al. who discovered that Atg16l1 
mutation in Paneth cells alone does not induce more severe injury 
in colon of DSS-induced colitis but a specific virus-plus-Atg16l1 
variant led to intestinal lesion in mice through secreting high lev-
els of TNF-α and interferon-γ (IFN-γ) (19). Furthermore, global 
knockout of Atg4b caused alterations in Paneth cell, including 
less number and small size of granules and decreased lysozyme, 
and Atg4b-deficient mice were more susceptible to DSS-induced 
colitis (77). In addition to autophagy-related genes, some other 
molecules can regulate the level of autophagy in intestinal epi-
thelial, like vitamin D receptor (VDR). The study showed that 
intestinal epithelial VDR deletion impaired antimicrobial func-
tion of Paneth cells by downregulation of Atg16l1 and lysozyme, 
thus causing increased susceptibility to DSS-induced colitis (78). 
Additional IBD risk gene, Nod2 or leucine-rich repeat kinase 2 
(LRRK2) absence disturbs the lysozyme packaging and secretion 
of Paneth cells, thus leading to the failure in controlling pathogen 
invasion, which was shown by infection with Listeria monocy-
togenes (79).
It is well known that dysfunction of ER causes unfolded and 
misfolded proteins accumulating in the ER lumen, which is called 
ER stress (80). ER stress disturbs the normal development and 
functions of cells, especially Paneth cells, because they are the 
IEC subtypes with the strongest function of secretion, which 
synthesize and excrete mounts of AMPs (81). As shown in recent 
discussion showed (82), there was a crosstalk between ER stress 
and inflammatory reaction. They noted that ER stress-induced 
inflammation in Paneth cells, epithelial cells, and goblet cells 
could possibly contribute to the pathogenesis and progression of 
IBD. However, they also argued that ER stress-induced inflam-
mation could impede tumorigenesis through the induction of 
immunogenic cellular death-based antitumor immune responses 
despite its already demonstrated contribution of tumorigenesis, 
thus indicating the complexity of relationship between ER stress-
induced inflammation and cancer. It was recently demonstrated 
that autophagy could be induced by ER stress in Paneth cells. 
The augmentation of autophagy in Paneth cells attenuates the 
ER stress-induced intestinal inflammation and eases nuclear 
factor-kappaB (NF-κB)-induced inflammatory reaction (72). 
This study uncovers the connection between autophagy and ER 
stress in the occurrence of IBD. In addition, it was reported that 
the ROS-mediated antibacterial autophagy (well-known as “xen-
ophagy”) as well as the mitochondrial autophagy (well-known as 
FiGURe 1 | Schematic illustration of impact of autophagy in Paneth cells, macrophages, and goblet cells in iBD. Under the exposure of DAMPs or 
PAMPs, autophagy process is induced in Paneth cells, macrophages, and goblet cells in the gut wall. (A) Autophagy in Paneth cells triggers the formation of 
functional granules and substantial release of the AMPs. In addition, autophagy suppresses pro-inflammatory cytokines secreted by Paneth cells. (B) In 
macrophages, autophagy promotes the degradation of pathogens and the presentation of antigens. Autophagy also inhibits the secretion of pro-inflammatory 
cytokines by macrophages. (C) In goblet cells, autophagy promotes the formation of mucins granules and secretion of mucins. IBD, inflammatory bowel disease; 
DAMPs, damage-associated molecular pattern molecules; PAMPs, pathogen- associated molecular patterns; AMPs, antimicrobial peptides.
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“mitophagy”) in Paneth cells contributed greatly to the attenua-
tion of IBD, thus probably serving as potential strategies for the 
treatment of IBD (83, 84). Collectively, these findings indicate 
that autophagy in epithelial cells, especially in Paneth cells, 
contributes to the alleviation of IBD (illustrated in Figure 1A).
Macrophage, iBD, and Autophagy
Macrophage and IBD
The intestinal mucosa holds the largest population of macrophages 
in the body, which are vital and essential for the maintenance of 
mucosal homeostasis and epithelial renewal as well as protection 
against pathogenic microorganisms (85, 86). For the ontogeny 
of the gut-resident macrophages, it was traditionally believed 
that the majority of tissue macrophages were derived from the 
mononuclear phagocyte system in the bone marrow (87). So far, 
it is widely acknowledged that macrophages of the gut wall share 
the markers, including CD11c and MHC II, with other antigen-
presenting cells like dendritic cells as well as “lineage-specifically” 
expressed CX3C chemokine receptor 1, F4/80, and CD64 (88, 89). 
Normally, macrophages are divided into M1 and M2 subtypes, 
the former displays pro-inflammatory characteristics and the 
later one has immunosuppressive and wound-healing properties 
(90). It was demonstrated that the gut-resident macrophages hold 
the features of both M1 and M2 subtypes. For instance, they have 
been reported to produce and secrete both the pro-inflammatory 
cytokines like TNF-α and the anti-inflammatory cytokines like 
IL-10, to adapt themselves to the environment of the gut wall 
(85, 91).
In the steady state, the gut-resident macrophages play an 
important role in the safeguarding of the intestine through the 
recognition and clearance of invading microorganisms and 
apoptotic cells as well as the regulation of tissue remodeling (92). 
The depletion of macrophages leads to the increasing susceptibil-
ity of DSS-induced colitis in mice (93). Intestinal macrophages 
can engulf and present the invading microorganisms to other 
immune cells like T cells, triggering the occurrence of immune 
reaction. Macrophages can also produce and secrete several 
pro-inflammatory cytokines and chemokines, including TNF-α, 
IL-6, IL-1β, and IL-12, leading to the further cascade amplifica-
tion of inflammatory reaction (88, 94). It was demonstrated that 
during the occurrence of DSS-induced colitis in mice model, a 
large extent of infiltration of pro-inflammatory monocytes and 
macrophages was observed, leading to the further triggering of 
inflammatory and immune reaction, thus indicating that the 
regulation of macrophage-mediated inflammatory and immune 
responses might be vital in the treatment of IBD (94).
The Roles of Macrophage Autophagy in IBD
The roles of macrophage autophagy are generally illustrated in 
Figure  1B. It has been proven that pathogenesis and progres-
sion of IBD is highly related to the constant and overwhelming 
activation of innate immune reaction in gut wall, leading to the 
secretion of pro-inflammatory cytokines and chemokines, thus 
resulting in mucosal damage (95). Macrophages are regarded 
as important innate immune cells, since macrophages sense 
pathogen-associated molecular patterns of microorganisms 
and DAMPs through PRRs to initiate rapid and effective innate 
immune response to protect organism against pathogens along 
with DCs (96). What’s more, macrophages recognize antigens 
and present them to T cells to induce adaptive immune response 
(97). Given the key role of the interactions between host and 
microbe in the intestine, it is critical to regulate PRR signals and 
cytokine secretion properly. The NOD-like receptors (NLRs) in 
cytoplasm and Toll-like receptors (TLRs) on the surface are the 
two main types of PRRs in innate immune cells (95). It has been 
demonstrated that NLRs and TLRs in macrophages as well as 
other innate immune cells are closely associated with autophagy, 
and macrophage autophagy is highly related to the mediation of 
FiGURe 2 | Schematic illustration of the impact of autophagy on 
NLRP3 inflammasome. Autophagy inducers promote autophagy process 
which inhibits the formation of NLRP3 inflammasome (integrated by NLRP3, 
ASC, and pro-caspase-1), thus suppressing the activation of caspase-1 and 
subsequent production of IL-1β. NLRP3, NLR family, pyrin domain-containing 
3; ASC, adapter protein apoptosis-associated speck-like protein; IL-1β, 
interleukin-1β.
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innate immune response in the gut wall (98, 99). For example, 
activating NOD2 using muramyldipeptide, a constituent of the 
bacterial peptidoglycan, recruited the autophagy-related protein 
ATG16L1 to the plasma membrane at the bacterial entry site to 
promote autophagy, but could not induce autophagy in cells with 
the Atg16l1 risk variant, thus indicating a functional connec-
tion between Nod2 and Atg16l1 (100–102). In addition, it was 
reported that macrophages with CD-associated Nod2 variants 
failed to induce autophagy, and the ability to kill pathogenic 
bacteria was impaired (103). Furthermore, there are much 
evidence of the connection between macrophage autophagy and 
the innate immune reaction in IBD. For instance, it was reported 
that impaired autophagy in macrophages transfected with siRNA 
targeted on Atg16l1 or IRGM and peritoneal macrophages from 
Nod2-deficient mice increased the amounts of intracellular 
adherent-invasive Escherichia coli (AIEC) and the levels of IL-6 
and TNF-α stimulated by AIEC (104). Moreover, downregulation 
of autophagy caused by Atg4b deficiency increased the suscepti-
bility to DSS-induced colitis, which is not only through affecting 
the function of Paneth cells but by promoting the production of 
pro-inflammatory cytokines in colon tissues from mice induced 
by DSS and in peritoneal macrophages stimulated with LPS (77). 
Those studies indicate that autophagy deficiency leads to the 
enhancement of the innate immune response and the production 
of pro-inflammatory cytokines in the gut wall with the inflam-
matory stress, thus demonstrating the close association between 
macrophage autophagy and the innate immune response in IBD.
Recently, a member of the NLR family, namely NLR fam-
ily, pyrin domain-containing 3 (NLRP3) inflammasome, has 
been implicated in the pathogenesis and progression of IBD 
(105–108). Among all kinds of inflammasomes, the NLRP3 
inflammasome is the best characterized one, containing NLRP3 
protein, adapter protein apoptosis-associated speck-like protein, 
and pro-caspase-1 (109, 110). Interactions among these three 
proteins tightly regulate inflammasome functions through 
inducing the production and secretion of IL-1β and IL-18, whose 
maturity is triggered by caspase-1 from their “pro” forms (110). 
It has been reported that the polymorphism in the Nlrp3 gene 
is closely associated with the colitis severity and progression in 
patients with IBD (111, 112). In addition, studies in macrophages 
and mice models of IBD have uncovered the link between the 
abnormal activation of the NLRP3 inflammasome and colitis 
(113, 114). It was recently reported that oral administration of 
titanium dioxide (TiO2) nanoparticles aggravated the severity of 
IBD through a mechanism involving the activation of the NLRP3 
inflammasome in DSS-induced colitis mice or UC patents 
(108). Studies have reported that the induction of macrophage 
autophagy produced an inhibitory effect on the activation of the 
NLRP3 inflammasome in different kinds of inflammation-related 
diseases, including multiple sclerosis and several kinds of cardio-
vascular diseases (115, 116). Impairing autophagy by Atg5 siRNA 
or 3-MA induced more robust initiation and activation of the 
NLRP3 inflammasome combined with increased caspase-1 acti-
vation and IL-1β production in peritoneal macrophages treated 
by LPS/DSS. Furthermore, using 3-MA to inhibit autophagy 
in vivo aggravated symptoms of DSS-induced colitis (117). Taken 
together, those results indicate that macrophage autophagy 
contributes to the alleviation of IBD through the inhibition of 
the NLRP3 inflammasome activation (illustrated in Figure  2). 
However, although the NLRP3 inflammasome has been shown to 
be highly related to the pathogenesis and progression of IBD and 
the crosstalk between autophagy and the NLRP3 inflammasome 
may probably provide a potential and promising therapeutic 
target for the treatment of IBD, yet the underlying mechanisms 
of IBD are not completely clear, and there is still a long way to go.
Goblet Cell, iBD, and Autophagy
Goblet Cell and IBD
Goblet cell is another critical kind of intestinal epithelial cell 
which is derived from the stem cells located in the crypt bottom. 
The main function of goblet cell is storage and secretion of large 
amount of mucin granules containing mucin glycoproteins like 
mucin 2, antimicrobial factors, and mucus cross-linking proteins 
like Fc-gamma binding protein, which combine with intestinal 
epithelium to form the first line of defense against gut flora 
from the host (118, 119). Since goblet cells are the most highly 
secretory cells among all kinds of intestinal epithelial cells, the 
increased mucins misfolding or decreased mucin glycoproteins 
secretion can induce ER stress and unfolded protein response. 
Both mucins depletion and ER stress give rise to the activation of 
inflammatory and immune responses and subsequent intestinal 
inflammation in mice (120–122). Consistently, dysfunction in 
mucins secretion and defective in mucus layer allow large quanti-
ties of bacteria to reach the epithelium and triggering excess host 
immune responses which has been demonstrated to be associated 
with IBD (123).
The Roles of Goblet Cell Autophagy in IBD
Recently, it has been revealed that autophagy could control the 
secretion function of goblet cells (illustrated in Figure 1C). Mice 
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or cells deficiency in autophagy by depletion of autophagy-related 
proteins like ATG5, ATG7, or LC3 led to altered goblet cell mor-
phology and significantly decreased mucins secretion (124, 125). 
In addition, mice expressing the ATG16l1 T300A variant exhib-
ited the similar characters of goblet cells (126). Patel et al. found 
out that nicotinamide adenine dinucleotide phosphate oxidase-
driven ROS production was required for autophagy-mediated 
secretion of goblet cells as Atg5-deficient spheroids produced 
significantly diminished ROS compared with those wild type, 
and these cells were overloaded with mucins. Furthermore, goblet 
cells from mice treated with ROS scavenger N-acetylcysteine were 
accumulated with mucins compared to controls (124). The accu-
mulated mucins in goblet cells suggested dysfunction in granules 
exocytosis. The upstream pathway inducing autophagy in goblet 
cells is mainly through activation of the NLRP6 inflammasome, 
a member of the Nod-like receptor family of PRRs. The NLRP6 
inflammasome promotes goblet cell mucin granules exocytosis 
by promoting autophagy and goblet cells from Nlrp6-deficient 
mice have impaired autophagy and are less effective in secreting 
mucins. This secretion alteration leads to significant impaired role 
of epithelial barrier in colonic host–microbial interactions (127, 
128). These findings suggest that defected autophagy in goblet 
cells contribute to the pathogenesis of IBD. Regulating autophagy 
in goblet cells may provide new strategies for the treatment of 
IBD. However, since the precise mechanisms and molecules 
involving autophagy in regulating mucins secretion are not fully 
elucidated, further studies are needed for the final clarification.
The Roles of Autophagy in Colorectal 
Cancer (CRC)
Since IBD is likely to develop into CRC in the end and autophagy 
plays a pivotal role in the pathogenesis of IBD as discussed above, 
it is quite necessary to pay attention to the effects of autophagy 
on colorectal carcinogenesis. Autophagy is regarded as a double-
edged sword during tumor progression, which suppresses tumor 
formation through inhibiting DNA injury, maintaining chro-
mosomal stability, reducing local inflammation, and promoting 
immune system to eliminate potentially tumorigenic cells (129). 
However, on the other hand, autophagy can promote cancer cell 
survival and proliferation by escaping from intracellular and 
environmental stress as well as resisting to anticancer agents (129). 
Hence, the relationship between autophagy and CRC is complex. 
The first aspect lies in the expression profile of autophagy in CRC. 
Some evidence has shown that autophagy is highly induced in 
most CRC patients and CRC cells (130–135). However, there 
is also a small population of CRC patients with downregulated 
autophagy (136). Based on those reports, the expression profile 
of autophagy is inconsistent in CRC patients.
The second aspect is the complexity of the roles of autophagy 
in CRC. It was previously reported that overexpression of 
Beclin-1 in vitro inhibited CRC cells growth and enhanced the 
rapamycin-induced antitumor effects (136). Patients with high 
levels of Beclin-1 presented good prognosis and longer survival 
(131, 135), and ATG10 downregulation was associated with cell 
migration and invasion of CRC cells (137). In addition, several 
compounds were recently demonstrated to suppress colorectal 
carcinogenesis through the induction of autophagy, including 
Salvianolic acid B and IR-58 (138, 139). Those findings indicate 
that promoting autophagy may probably provide an effective strat-
egy for the treatment of CRC. However, enhancing autophagy is 
not without its problems in the treatment of CRC. It was reported 
that promoting autophagy could enhance CRC cells tolerance 
to antitumor drugs (140, 141). For example, patients with high 
levels of Beclin-1 resist 5-FU-based adjuvant therapy and result 
in a poor prognosis and metastasis (142, 143). In addition, sup-
pressing autophagy by deletion of Atg5 enhanced the sensitivity 
of CRC cells and CRC mice to oxaliplatin and INF-γ (144, 145). 
In conclusion, since the functions of autophagy in CRC are com-
plicated, to ultimately develop autophagy as therapeutic strategy 
in the treatment of CRC, numerous studies are needed in seek of 
effective approaches to induce autophagy while getting rid of its 
side effects.
PHARMACOLOGiCAL iNTeRveNTiON OF 
AUTOPHAGY iN THe TReATMeNT OF iBD
In consideration of the importance of autophagy in the pathag-
enesis and progression of IBD, numerous studies have been 
conducted so far, focusing on the alleviation and treatment of 
IBD through the regulation of autophagy.
Herbal extracts
Andrographolide belongs to diterpenoids extracted from a 
kind of herb called andrographolide. Andrographolide has 
anti-inflammatory and antitumor activity (146, 147), and it 
can effectively inhibit the growth of breast and colon cancer 
cells (148). The combination of andrographolide and radiation 
therapy can enhance the levels of apoptosis and autophagy in 
nude mice xenografted by human ovarian cancer skov3 (149). 
It was reported that andrographolide sulfonate could inhibit 
the p38 mitogen-activated protein kinase (p38 MAPK) and 
NF-κB signaling pathways, which contributed to the reduction 
of pro-inflammatory cytokines production in trinitrobenzene 
sulfonic acid (TNBS)-induced colitis mice model and further 
intervened the progression of colitis (150). In addition, Guo 
et  al. (151) demonstrated that andrographolide could enhance 
mitophagy in macrophages, lead to the reverse of mitochondrial 
membrane potential, and thus alleviate the symptoms of DSS-
induced colitis through the inhibition of NLRP3 inflammasome 
activity. However, several autophagy inhibitors, including 3-MA, 
chloroquine, bafilomycin A1, or Becline 1 siRNA abolished the 
inhibitory effects of andrographolide on the NLRP3 inflamma-
some and to a large extent reduced the therapeutic effects of 
andrographolide for colitis.
Another herbal extract worth mentioning is celastrol. It is 
a kind of triterpenoid extracted from the root of a traditional 
Chinese medicine called Tripterygium wilfordii. It was reported 
that celastrol could inhibit the development of IBD or colitis 
through several pathways, including: (1) regulating the oxidative 
stress and reducing lipid peroxide; (2) inhibiting the activa-
tion of the NLRP3 inflammasome; (3) increasing the levels 
of anti-inflammatory cytokines like IL-10; (4) enhancing the 
stability of intestinal epithelial barrier (152); (5) inhibiting the 
receptor interacting-protein 3/mixed lineage kinase domain-like 
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protein-mediated programed necrosis pathway (153); and (6) 
inhibiting the production of NF-κB and its related inflammatory 
cytokines (154). Furthermore, it has been proven that celastrol 
can enhance the level of autophagy through the inhibition of 
the PI3K/Akt/mTOR signaling pathway in the colon tissue, and 
meanwhile reduce the production of several pro-inflammatory 
cytokines thus attenuating the inflammatory reaction in colon 
in IL-10-deficient mice (155). Based on those findings, it is 
reasonable to believe that those two herbal extracts may provide 
promising and effective therapies for IBD. However, since the 
clinical data for the treatment of IBD are poor, more detailed 
clinical studies are needed to explore their effectiveness and safety 
on IBD patients.
Receptor Regulators
As been discussed above, the activation of the NLRP3 inflam-
masome leads to the activation of caspase-1, which induces the 
transformation of proIL-1β and proIL-18 into the mature IL-1β 
and IL-18. The maturation of IL-1β and IL-18 contributes to the 
pathogenesis and progression of inflammatory diseases. Studies 
indicated that autophagy play an important role in the forma-
tion and activation of NLRP3 inflammasome, and autophagy 
deficiency led to the abnormal increase of IL-1β (156–158). 
Mice deficient in autophagy showed more severe symptoms of 
colitis (59). Recently, increasing studies are conducted to explore 
whether blocking IL-1β contributes to alleviating the progres-
sion of IBD. For example, De Luca et  al. (159) found out that 
the blockade of IL-1β receptor using anakinra could effectively 
alleviate the progression of IBD through the reduction of neu-
trophils accumulation and Th17 cell response. Van De Veerdonk 
and Dinarello (49) demonstrated that anakinra could restore the 
autophagy level of patients with chronic granuloma and reduced 
the IL-1-mediated inflammatory reaction, thus playing a protec-
tive role in the TNBS-induced colitis and alleviating the severity 
of patients with chronic granuloma, promoting the recovery of 
rectal abscess.
Cannabinoid receptor 2 (CB2R) is a kind of seven 
transmembrane-spanning G protein coupled receptor, mainly 
distributing on immune cells (160). Activating CB2R has been 
reported to contribute to the alleviation of EAE through the 
increase of autophagy, which in turn led to the inhibition of the 
NLRP3 inflammasome (115). Nowadays, the role of CB2R in 
IBD or colitis has been widely recognized. For example, it has 
been reported that activating CB2R can attenuate the severity of 
colitis in wild-type mice (161). In addition, activating CB2R was 
also demonstrated to alleviate colitis through inhibiting T cell 
activation and promote apoptosis in IL-10-deficient mice (162). 
In the recent years, several kinds of CB2R activators have been 
successfully applied in the treatment of colitis animal model (117, 
163, 164). For example, activating CB2R by HU-308, a selective 
CB2R agonist, contributed to the enhancement of macrophage 
autophagy through the AMPK-mTOR-P70S6K signaling path-
way, and further inhibited the NLRP3 inflammasome activation, 
thus reducing the level of IL-1β and alleviating the progression 
of DSS-induced colitis in mice (117) (illustrated in Figure  2). 
So far, although studies uncovered the promising therapeutic 
value of CB2R activators in the treatment of IBD, there is still no 
related drug taking advantage of the beneficial effects of activat-
ing CB2R for IBD. Hence, further studies are demanded for the 
development of related drugs and in the other hand, more kinds 
of receptor regulators should be fully studied to serve for the 
treatment of IBD.
Nutrient Molecules
Vitamin D deficiency is regarded as an important pathological 
basis of IBD (165). Studies showed that the level of vitamin D is 
relatively low in patients with IBD (166, 167). Vitamin D leads to 
a series of physiological effects mainly through functioning on 
VDR, of which the gene polymorphism is closely connected with 
the susceptibility of IBD (168). It was reported that deficiency in 
vitamin D can lead to the reduction of ATG16L1 and the level 
of autophagy and further influenced the function of Paneth 
cells. After restoring the level of VDR by applying vitamin D3 in 
intestinal epithelial cells, the levels of autophagy is increased (78). 
Furthermore, a systematic review and meta-analysis conducted 
by Ma et al. (169) demonstrated that vitamin D intake as well as 
blood 25(OH)D levels were inversely associated with the risk of 
CRC. In consideration of the closely relationship between IBD 
and CRC, the antitumor feature of vitamin D provides further 
evidence to show the therapeutic value of vitamin D in the treat-
ment of IBD.
Glutamine is a kind of free amino acid widely distributed in 
organisms. It is the respiratory material and metabolic precur-
sors of many kinds of cells, including intestinal epithelial cells 
and immune cells (170–172). Under the physiological stress, 
glutamine reduces the permeability of intestinal epithelial cells, 
inhibits intestinal mucosa injury, and promotes the intestinal res-
toration (173–175). It was reported that in the intestinal epithelial 
cells glutamine contributed to the enhancement of autophagy 
level in the basal and stressing condition through the regulation 
of the mTOR and p38 MAPK signaling pathway, thus inhibiting 
the stress-induced cellular apoptosis (176).
Other Small-Molecular Compounds
Two kinds of rapamycin analogs, namely, sirolimus and everoli-
mus, which have already been applied in clinic, contribute to 
the enhancement of autophagy level. It has been reported that 
continuous application of sirolimus for 6 months significantly led 
to the attenuation of symptoms in patients with severe recurrent 
CD (177). Sirolimus can not only benefit adult IBD patients, 
but also lead to the alleviation of IBD in the children patients. 
It was reported that after the application of sirolimus, 45% UC 
patients and 100% CD patients reached the clinical stable stage. 
Meanwhile, sirolimus contributes to the promotion of intestinal 
mucus restoration (178). In addition, after the occurrence of the 
spontaneous colitis in IL-10-deficient mice, researchers found out 
that treating with everolimus for 4 weeks significantly reduced the 
disease activity index as well as the infiltration of lymphocytes 
in spleen, mesenteric lymph nodes, and inherent layer (179). It 
was lately reported by Dumortier et  al. (180) that after treated 
with everolimus in the original treatment therapy for 1½ years, 
the symptoms in a patient with refractory UC were effectively 
controlled. However, in a multicenter randomized double bind 
trial, everolimus was not beneficial for the maintenance of the 
TABLe 1 | The mechanisms of autophagy inducers in treatment of iBD.
Category Name Mechanism Reference
Herbal 
extract
Andrographolide Inhibits NLRP3 inflammasome (151)
Celastrol Reduces pro-inflammatory 
cytokines production
(155)
Receptor 
regulator
Interleukin-1β 
receptor blocker
Reduces neutrophils 
accumulation and Th17 cell 
response
(49, 159)
CB2 receptor 
agonist
Inhibits NLRP3 inflammasome (117)
Nicotine Increases cyclooxygenase-2 and 
prostaglandin E2
(182)
Nutrient 
molecular
Vitamine D3 Restores vitamin D receptor level (78, 183, 
184)
Glutamine Inhibits cellular apoptosis (176)
Docosahexaenoic 
acid
Inhibits the mTOR signaling 
pathway
(185)
Other small-
molecular 
compound
Sirolimus Promotes intestinal mucus 
restoration
(177, 178)
Everolimus Reduce lymphocytes infiltration (179, 180)
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stable stage treated with glucocorticoid in patients with activity 
stage in the present of placebo or azathioprine (181). This study 
indicates that the therapeutic strategy for IBD through enhancing 
autophagy process demands further assessment and the effective-
ness and security needs further tested.
The drugs or molecules mentioned above that alleviate IBD 
through enhancing autophagy were listed in the Table  1, and 
some other drugs were also briefly mentioned.
CONCLUSiON
Intestinal autophagy, especially autophagy in Paneth cells, 
macrophages, and goblet cells in the intestinal wall, produces 
an alleviative effect on the pathogenesis and progression of IBD. 
In the recent few years, we are pleased to have several kinds of 
drugs developed for the treatment of IBD taking advantage of 
the induction of autophagy, including herbal extracts, recep-
tor regulators, nutrient molecules, and other small-molecular 
compounds, etc. However, despite the numerous therapeutic 
strategies available, there is still no effective way for the treatment 
of IBD. Furthermore, the specific mechanism of IBD still remains 
uncovered. Besides, there are several other hot-discussed issues 
worth mentioning in this field: first, since little literatures have 
reported the effects of autophagy inducers in the clinical treat-
ment of IBD, proper doses demand further testing and side effects 
ought to be found out for the safe application. Second, based on 
the discussion above, although inducing autophagy contributes 
to the alleviation of IBD, yet it has already been reported that 
on certain conditions, the induction of autophagy may also lead 
to inverse effects on the attenuation of IBD (186–188). Third, as 
discussed above, although inducing autophagy contributes to the 
suppression of colorectal carcinogenesis, there are still side effects 
that autophagy inducers may lead to the enhancement of CRC 
cells tolerance to antitumor drugs. Therefore, more studies are 
needed to explore the mechanisms of IBD, and effective thera-
peutic strategies are demanded to be developed while getting rid 
of side effects of inducing autophagy.
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